Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) generates frequent news through its work as a biopharmaceutical company focused on cardiovascular indications and diseases with unmet need. Company press releases and Form 8‑K filings highlight developments around its IL‑1 pathway franchise, including the commercial performance of ARCALYST (rilonacept) and the clinical progress of investigational monoclonal antibodies KPL‑387 and KPL‑1161.
News items commonly cover quarterly and annual financial results, where Kiniksa reports ARCALYST net product revenue, trends in prescriber adoption, and changes in guidance for expected ARCALYST net product revenue. These updates often include commentary on the uptake of IL‑1α and IL‑1β inhibition in recurrent pericarditis, the proportion of multiple‑recurrence patients on ARCALYST therapy, and the average duration of treatment.
Investors following KNSA news also see regular clinical and regulatory milestones. Kiniksa has announced the initiation and design of a Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, Phase 1 data supporting a monthly dosing profile, and the U.S. FDA’s Orphan Drug Designation for KPL‑387 for the treatment of pericarditis. Additional updates describe preclinical or IND‑enabling activities for KPL‑1161, which has a target profile of quarterly subcutaneous dosing.
Corporate and investor‑relations announcements form another key part of the KNSA news flow. The company frequently issues notices about upcoming and completed presentations at healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference, Jefferies Global Healthcare Conference, and other biopharma‑focused events. These communications typically reference webcasts and replays available through Kiniksa’s investor channels.
By monitoring this news stream, readers can track how Kiniksa manages ARCALYST commercialization, advances its IL‑1R1‑targeted pipeline, and updates its financial outlook. The KNSA news page on Stock Titan aggregates these releases so investors and observers can review earnings announcements, trial updates, regulatory designations, and conference participation in one place.
Kiniksa Pharmaceuticals (KNSA) has announced the issuance of U.S. Patent No. 11,026,997, covering methods for using ARCALYST® (rilonacept) in treating recurrent pericarditis, which will expire on March 11, 2039. This patent strengthens Kiniksa's proprietary position and extends protection beyond orphan drug exclusivity. CEO Sanj K. Patel highlighted the upcoming full quarter sales report for ARCALYST in Q2. Recurrent pericarditis affects around 40,000 U.S. patients annually, with significant quality of life impacts.
Kiniksa Pharmaceuticals has defined a regulatory path for the Phase 3 clinical development of mavrilimumab, targeting multiple indications including COVID-19-related ARDS, giant cell arteritis, and rheumatoid arthritis. Mavrilimumab's ongoing Phase 3 trial in COVID-19-related ARDS aims for rapid registration, with results expected in Q1 2022. The trial will enroll approximately 600 patients, progressing from promising Phase 2 results. Kiniksa maintains a solid cash reserve of $264 million, supporting operations into 2023.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) announced its participation in the Goldman Sachs 42nd Annual Global Healthcare Conference, scheduled for June 8, 2021, at 9:40 a.m. Eastern Time. The presentation will be available via a live webcast on the company's website, with a replay accessible for 14 days post-event. Kiniksa focuses on developing therapeutic medicines for patients with significant unmet medical needs, with products including ARCALYST (rilonacept) and others designed to target immunological pathways.
Kiniksa Pharmaceuticals announced a transformative first quarter 2021, highlighted by the FDA approval of ARCALYST for recurrent pericarditis, the first approved therapy for this condition. The commercial launch began in April 2021. The company also reported positive data for mavrilimumab in severe COVID-19 pneumonia and plans to initiate a Phase 2 trial for KPL-404 in rheumatoid arthritis. However, Q1 2021 net loss increased to $49.5 million from $26.4 million a year ago. As of March 31, 2021, Kiniksa holds $264 million in cash, expected to support operations into 2023.
Kiniksa Pharmaceuticals (KNSA) announced positive final data from its Phase 1 trial of KPL-404, a monoclonal antibody targeting the CD40-CD154 pathway. The 10 mg/kg IV dose showed full receptor occupancy through Day 71 and complete suppression of the T-cell dependent antibody response (TDAR) after KLH challenge for at least 57 days. The 5 mg/kg SC dose achieved full receptor occupancy through Day 43. Kiniksa plans to initiate a Phase 2 proof-of-concept trial in rheumatoid arthritis patients in the second half of 2021, aiming to explore chronic dosing and potential efficacy in various autoimmune diseases.
Kiniksa Pharmaceuticals (KNSA) announced that the Phase 2 trial of mavrilimumab in non-mechanically-ventilated patients with severe COVID-19 pneumonia achieved its primary efficacy endpoint. The trial showed that patients treated with mavrilimumab had a 12.3 percentage point higher survival rate without mechanical ventilation at Day 29 compared to placebo (86.7% vs. 74.4%). Additionally, there was a 65% reduction in the risk of mechanical ventilation or death (p=0.0175) and a 61% reduction in death risk (p=0.0726). The company is in discussions with regulatory agencies to expedite mavrilimumab's availability.
Kiniksa Pharmaceuticals announced the commercial availability of ARCALYST (rilonacept), the first FDA-approved treatment for recurrent pericarditis, effective March 18, 2021. This therapy is available for patients aged 12 and older and aims to reduce recurrence risk. Kiniksa is committed to patient support through its Kiniksa One Connect™ program, offering access and affordability solutions. The drug is distributed via specialty pharmacies across the U.S. Kiniksa will profit-share with Regeneron under the licensing agreement, which includes support for additional indications.
Kiniksa Pharmaceuticals has announced that the FDA approved ARCALYST (rilonacept), the first and only therapy for recurrent pericarditis, which impacts approximately 40,000 patients annually in the U.S. The approval is based on the promising results from the pivotal RHAPSODY Phase 3 trial, which demonstrated a 96% reduction in the risk of pericarditis recurrence. The commercial launch is set for April 2021. Kiniksa will also support patients through the Kiniksa One Connect™ program for enhanced access and affordability.
Kiniksa Pharmaceuticals has launched the RESONANCE registry to better understand the management of recurrent pericarditis, a debilitating cardiovascular disease. The registry aims to collect uniform data from physicians and patients, enhancing insights into treatment practices. Supported by expert physician-researchers and patient advocates, RESONANCE will gather patient-reported outcomes and observational data. Approximately 20 sites in the US will participate, starting in 2021, addressing the unmet medical needs of this underserved condition.
Kiniksa Pharmaceuticals reported a net loss of $53.7 million in Q4 2020, compared to $31.8 million in Q4 2019, and a net loss of $161.4 million for the full year. Total operating expenses fell to $157.4 million for 2020 versus $170.0 million in 2019. The company anticipates launching rilonacept in recurrent pericarditis in 1H 2021, pending FDA approval. With approximately $323 million in cash reserves, Kiniksa is well-positioned to fund operations into 2023. Upcoming clinical data from KPL-404 and mavrilimumab is expected in 1H 2021.